SGLT2 Inhibitor—Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism

SGLT2 Inhibitor—Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism

Diabetic kidney disease (DKD) is a serious complication of diabetes, affecting millions of people worldwide. Inflammation and oxidative stress are key contributors to the development and progression of DKD, making them potential targets for therapeutic interventions. Sodium-glucose cotransporter 2 i...

Full description

Bibliographic Details
Main Authors: Batoul Dia, Sahar Alkhansa, Rachel Njeim, Sarah Al Moussawi, Theresa Farhat, Antony Haddad, Mansour E. Riachi, Rashad Nawfal, William S. Azar, Assaad A. Eid
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Pharmaceutics
Subjects:
diabetic kidney disease
SGLT2 inhibitor
20-HETE
oxidative stress
inflammatory markers
Online Access:https://www.mdpi.com/1999-4923/15/3/965

Internet

https://www.mdpi.com/1999-4923/15/3/965

Similar Items